BACKGROUND: This study examined the prevalence and risk factors of persistent (versus short-term) depressive symptoms in patients with head and neck cancer. METHODS: Patients with 10+ and 18+ posttreatment Beck Depression Inventory scores for 6 or more months during their first year were identified. Regression analyses determined risk factors associated with persistently high scores. RESULTS: Of the 148 patients, 25.0% and 7.4% were persistently above the 10+ and 18+ cutoff scores, respectively (compared with 33.6% to 44.2% and 9.2% to 18.6% when measured at single points across this time period.) The strongest predictor of persistent posttreatment depressive symptoms was pretreatment depressive symptoms. CONCLUSIONS: The percentage of patients with persistently high levels of depressive symptoms, although considerable, is substantially lower when patients with transient mood disorders are omitted. A screening tool that determines high levels of pretreatment depressive symptoms could identify patients at high risk of experiencing posttreatment depression who would be good candidates for clinical intervention. Copyright 2005 Wiley Periodicals, Inc.
BACKGROUND: This study examined the prevalence and risk factors of persistent (versus short-term) depressive symptoms in patients with head and neck cancer. METHODS:Patients with 10+ and 18+ posttreatment Beck Depression Inventory scores for 6 or more months during their first year were identified. Regression analyses determined risk factors associated with persistently high scores. RESULTS: Of the 148 patients, 25.0% and 7.4% were persistently above the 10+ and 18+ cutoff scores, respectively (compared with 33.6% to 44.2% and 9.2% to 18.6% when measured at single points across this time period.) The strongest predictor of persistent posttreatment depressive symptoms was pretreatment depressive symptoms. CONCLUSIONS: The percentage of patients with persistently high levels of depressive symptoms, although considerable, is substantially lower when patients with transient mood disorders are omitted. A screening tool that determines high levels of pretreatment depressive symptoms could identify patients at high risk of experiencing posttreatment depression who would be good candidates for clinical intervention. Copyright 2005 Wiley Periodicals, Inc.
Authors: Julia R Van Liew; Rebecca L Brock; Alan J Christensen; Lucy Hynds Karnell; Nitin A Pagedar; Gerry F Funk Journal: Head Neck Date: 2016-10-05 Impact factor: 3.147
Authors: Laura H A Korsten; Femke Jansen; Ben J F de Haan; Danielle Sent; Pim Cuijpers; C René Leemans; Irma M Verdonck-de Leeuw Journal: Psychooncology Date: 2019-05-09 Impact factor: 3.894
Authors: Anne-Marie H Krebber; C René Leemans; Remco de Bree; Annemieke van Straten; Filip Smit; Egbert F Smit; Annemarie Becker; Guus M Eeckhout; Aartjan T F Beekman; Pim Cuijpers; Irma M Verdonck-de Leeuw Journal: BMC Cancer Date: 2012-05-10 Impact factor: 4.430